Revolution Medicine reported standout Phase III results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma, generating a sharp investor reaction. In RASolute 302 (NCT06625320), the once-daily oral therapy delivered median overall survival of 13.2 months in the intent-to-treat population versus 6.7 months with standard-of-care chemotherapy, with a hazard ratio of 0.40. The company framed the dataset as exceeding expectations and said it is moving quickly toward global regulatory submissions. Analysts cited the magnitude of the overall survival gap versus chemotherapy as a key driver of the view that the results represent a “best-case outcome.” The market response reportedly included a rapid stock jump after the data release, reflecting how Phase III pancreatic oncology readouts can reset perceived odds for new targeted therapies. The next inflection point will be how regulators and future analyses interpret efficacy alongside safety and consistency of benefit.